Compare Quest Diagnostics Inc (DGX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Plby Group Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Plby Group Inc trades at $1.33 (market cap $162.94M). The key difference: Quest Diagnostics Inc is far larger — about 160.9× Plby Group Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| DGX | PLBY | |
|---|---|---|
Market Cap | $26.21B | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $2.71 |
52-Week Low | $173.49 | $1.11 |
Enterprise Value | $31.97B | $308.52M |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
PLBY Group trades at $1.255, up 6.36% with bullish technical signals from moving averages. The company shows improving fundamentals with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains thin at 0.23%. Recent developments include inclusion in Russell indexes and strategic share repurchases. Analyst consensus is strongly positive with 75% buy ratings.
The outlook suggests gradual recovery with projected 2026 profitability, though high P/E of 68 and negative shareholder equity pose valuation concerns. Key opportunities include licensing growth and brand expansion, while risks involve debt burden and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
